Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.76B 1.53B 1.42B 1.31B 2.47B 167B 2.5B 16.77B 6.56B 83.54B 6.6B 6.45B 277B P/E 2026 *
-3.8x
P/E 2027 * -3.54x
Enterprise Value 1.31B 1.14B 1.06B 977M 1.85B 125B 1.87B 12.54B 4.9B 62.46B 4.93B 4.82B 207B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 17.6x
Free-Float
96.67%
Yield 2026 *
-
Yield 2027 * -
1 day+4.09%
1 week+8.52%
Current month+10.33%
1 month-12.89%
3 months-5.97%
6 months-15.13%
Current year-19.07%
1 week 2.95
Extreme 2.95
3.36
1 month 2.84
Extreme 2.84
4.09
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
31.43
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Sell

Founder

-40,000 0.0076%
7/1/26 Free

Founder

3,747 0.0007%
7/1/26 Free

Director

5,109 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+4.09%+8.52%-42.93%-73.31% 1.76B
+10.00%+14.90%+53.89%+87.07% 62.53B
+0.80%-5.70%+23.89%+62.65% 52.43B
-0.98%-1.19%-16.98%-14.21% 23.1B
+0.30%-5.17%-11.23%+349.07% 21.4B
+1.73%-1.57%+32.81%-25.80% 17.76B
+4.29%+8.97%+200.03%+341.85% 15.47B
+2.86%-0.52%+14.32%+617.39% 14.68B
+1.71%-0.90%+52.13%+176.27% 14.08B
+4.16%+4.44%+444.12%+183.06% 12.62B
Average +2.88%+1.74%+75.01%+170.40% 23.58B
Weighted average by Cap. +3.70%+1.88%+59.96%+145.99%

Financials

2026 *2027 *
Net sales 64.74M 56.21M 52.41M 48.15M 91.06M 6.16B 92.06M 618M 242M 3.08B 243M 238M 10.2B 83.76M 72.73M 67.81M 62.3M 118M 7.97B 119M 799M 313M 3.98B 315M 308M 13.2B
Net income -453M -394M -367M -337M -637M -43.11B -644M -4.33B -1.69B -21.55B -1.7B -1.66B -71.41B -525M -456M -425M -390M -738M -49.93B -746M -5.01B -1.96B -24.96B -1.97B -1.93B -82.7B
Net Debt -443M -385M -359M -330M -624M -42.17B -630M -4.23B -1.65B -21.08B -1.66B -1.63B -69.84B -285M -248M -231M -212M -401M -27.14B -406M -2.72B -1.06B -13.57B -1.07B -1.05B -44.95B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-08-04 US$3.310 +4.09% 21,577,753
26-08-03 US$3.180 +6.00% 14,721,783
26-07-31 US$3.000 -1.32% 15,329,356
26-07-30 US$3.040 +2.36% 10,409,906
26-07-29 US$2.970 -2.62% 17,954,125
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.310USD
Average target price
7.250USD
Spread / Average Target
+119.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock